1,506 results on '"Bhasin, Shalender"'
Search Results
2. Factors Associated With Circulating Sex Hormones in Men : Individual Participant Data Meta-analyses.
- Author
-
Bhasin, Shalender, Biggs, Mary, Cawthon, Peggy, Couper, David, Dobs, Adrian, Flicker, Leon, Handelsman, David, Hankey, Graeme, Hannemann, Anke, Haring, Robin, Hsu, Benjumin, Karlsson, Magnus, Martin, Sean, Matsumoto, Alvin, Mellström, Dan, Ohlsson, Claes, ONeill, Terence, Orwoll, Eric, Quartagno, Matteo, Shores, Molly, Steveling, Antje, Tivesten, Åsa, Travison, Thomas, Vanderschueren, Dirk, Wittert, Gary, Wu, Frederick, Yeap, Bu, Marriott, Ross, Murray, Kevin, Adams, Robert, Antonio, Leen, Ballantyne, Christie, and Bauer, Douglas
- Subjects
Humans ,Male ,Adolescent ,Young Adult ,Adult ,Middle Aged ,Aged ,Sex Hormone-Binding Globulin ,Cross-Sectional Studies ,Prospective Studies ,Gonadal Steroid Hormones ,Testosterone ,Luteinizing Hormone - Abstract
BACKGROUND: Various factors modulate circulating testosterone in men, affecting interpretation of testosterone measurements. PURPOSE: To clarify factors associated with variations in sex hormone concentrations. DATA SOURCES: Systematic literature searches (to July 2019). STUDY SELECTION: Prospective cohort studies of community-dwelling men with total testosterone measured using mass spectrometry. DATA EXTRACTION: Individual participant data (IPD) (9 studies; n = 21 074) and aggregate data (2 studies; n = 4075). Sociodemographic, lifestyle, and health factors and concentrations of total testosterone, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), dihydrotestosterone, and estradiol were extracted. DATA SYNTHESIS: Two-stage random-effects IPD meta-analyses found a nonlinear association of testosterone with age, with negligible change among men aged 17 to 70 years (change per SD increase about the midpoint, -0.27 nmol/L [-7.8 ng/dL] [CI, -0.71 to 0.18 nmol/L {-20.5 to 5.2 ng/dL}]) and decreasing testosterone levels with age for men older than 70 years (-1.55 nmol/L [-44.7 ng/dL] [CI, -2.05 to -1.06 nmol/L {-59.1 to -30.6 ng/dL}]). Testosterone was inversely associated with body mass index (BMI) (change per SD increase, -2.42 nmol/L [-69.7 ng/dL] [CI, -2.70 to -2.13 nmol/L {-77.8 to -61.4 ng/dL}]). Testosterone concentrations were lower for men who were married (mean difference, -0.57 nmol/L [-16.4 ng/dL] [CI, -0.89 to -0.26 nmol/L {-25.6 to -7.5 ng/dL}]); undertook at most 75 minutes of vigorous physical activity per week (-0.51 nmol/L [-14.7 ng/dL] [CI, -0.90 to -0.13 nmol/L {-25.9 to -3.7 ng/dL}]); were former smokers (-0.34 nmol/L [-9.8 ng/dL] [CI, -0.55 to -0.12 nmol/L {-15.9 to -3.5 ng/dL}]); or had hypertension (-0.53 nmol/L [-15.3 ng/dL] [CI, -0.82 to -0.24 nmol/L {-23.6 to -6.9 ng/dL}]), cardiovascular disease (-0.35 nmol/L [-10.1 ng/dL] [CI, -0.55 to -0.15 nmol/L {-15.9 to -4.3 ng/dL}]), cancer (-1.39 nmol/L [-40.1 ng/dL] [CI, -1.79 to -0.99 nmol/L {-51.6 to -28.5 ng/dL}]), or diabetes (-1.43 nmol/L [-41.2 ng/dL] [CI, -1.65 to -1.22 nmol/L {-47.6 to -35.2 ng/dL}]). Sex hormone-binding globulin was directly associated with age and inversely associated with BMI. Luteinizing hormone was directly associated with age in men older than 70 years. LIMITATION: Cross-sectional analysis, heterogeneity between studies and in timing of blood sampling, and imputation for missing data. CONCLUSION: Multiple factors are associated with variation in male testosterone, SHBG, and LH concentrations. Reduced testosterone and increased LH concentrations may indicate impaired testicular function after age 70 years. Interpretation of individual testosterone measurements should account particularly for age older than 70 years, obesity, diabetes, and cancer. PRIMARY FUNDING SOURCE: Medical Research Future Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: CRD42019139668).
- Published
- 2023
3. Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy
- Author
-
Tesch, Megan E., Zheng, Yue, Rosenberg, Shoshana M., Poorvu, Philip D., Ruddy, Kathryn J., Tamimi, Rulla, Schapira, Lidia, Peppercorn, Jeffrey, Borges, Virginia, Come, Steven E., Snow, Craig, Bhasin, Shalender, and Partridge, Ann H.
- Published
- 2024
- Full Text
- View/download PDF
4. Synergistic Strategies to Accelerate the Development of Function-Promoting Therapies: Lessons From Operation Warp Speed and Oncology Drug Development.
- Author
-
Correa-de Araujo, Rosaly, Evans, William, Fielding, Roger, Krishnan, Venkatesh, Carter, Robert, Appleby, James, Guralnik, Jack, Klickstein, Lloyd, Marks, Peter, Moore, Alison, Peschin, Sue, and Bhasin, Shalender
- Subjects
Age-related skeletal muscle dysfunction ,Function-promoting therapies ,Mobility-disability ,Sarcopenia ,Skeletal muscle function deficit ,United States ,Humans ,COVID-19 Vaccines ,COVID-19 ,National Institutes of Health (U.S.) ,Drug Development - Abstract
BACKGROUND: Functional limitations and physical disabilities associated with aging and chronic disease are major concerns for human societies and expeditious development of function-promoting therapies is a public health priority. METHODS: Expert panel discussion. RESULTS: The remarkable success of Operation Warp Speed for the rapid development of COVID-19 vaccines, COVID-19 therapeutics, and of oncology drug development programs over the past decade have taught us that complex public health problems such as the development of function-promoting therapies will require collaboration among many stakeholders, including academic investigators, the National Institutes of Health, professional societies, patients and patient advocacy organizations, the pharmaceutical and biotechnology industry, and the U.S. Food and Drug Administration. CONCLUSIONS: There was agreement that the success of well designed, adequately powered clinical trials will require careful definitions of indication/s, study population, and patient-important endpoints that can be reliably measured using validated instruments, commensurate resource allocation, and versatile organizational structures such as those used in Operation Warp Speed.
- Published
- 2023
5. Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies.
- Author
-
Bhasin, Shalender, Cawthon, Peggy, Correa-de-Araujo, Rosaly, Storer, Thomas, Volpi, Elena, Newman, Anne, Dioh, Waly, Tourette, Cendrine, Evans, William, and Fielding, Roger
- Subjects
Clinical trial design ,Function-promoting drugs ,Functional decline with aging ,Sarcopenia ,Skeletal muscle dysfunction ,Aged ,Humans ,Aging ,Frailty ,Neoplasms ,Sarcopenia ,Clinical Trials as Topic - Abstract
BACKGROUND: Several candidate molecules that may have application in treating physical limitations associated with aging and chronic diseases are in development. Challenges in the framing of indications, eligibility criteria, and endpoints and the lack of regulatory guidance have hindered the development of function-promoting therapies. METHODS: Experts from academia, pharmaceutical industry, National Institutes of Health (NIH), and Food and Drug Administration (FDA) discussed optimization of trial design including the framing of indications, eligibility criteria, and endpoints. RESULTS: Mobility disability associated with aging and chronic diseases is an attractive indication because it is recognized by geriatricians as a common condition associated with adverse outcomes, and it can be ascertained reliably. Other conditions associated with functional limitation in older adults include hospitalization for acute illnesses, cancer cachexia, and fall injuries. Efforts are underway to harmonize definitions of sarcopenia and frailty. Eligibility criteria should reconcile the goals of selecting participants with the condition and ensuring generalizability and ease of recruitment. An accurate measure of muscle mass (eg, D3 creatine dilution) could be a good biomarker in early-phase trials. Performance-based and patient-reported measures of physical function are needed to demonstrate whether treatment improves how a person lives, functions, or feels. Multicomponent functional training that integrates training in balance, stability, strength, and functional tasks with cognitive and behavioral strategies may be needed to translate drug-induced muscle mass gains into functional improvements. CONCLUSIONS: Collaborations among academic investigators, NIH, FDA, pharmaceutical industry, patients, and professional societies are needed to conduct well-designed trials of function-promoting pharmacological agents with and without multicomponent functional training.
- Published
- 2023
6. Effect of the STRIDE fall injury prevention intervention on falls, fall injuries, and health‐related quality of life
- Author
-
Ganz, David A, Yuan, Anita H, Greene, Erich J, Latham, Nancy K, Araujo, Katy, Siu, Albert L, Magaziner, Jay, Gurwitz, Jerry H, Wu, Albert W, Alexander, Neil B, Wallace, Robert B, Greenspan, Susan L, Rich, Jeremy, Volpi, Elena, Waring, Stephen C, Dykes, Patricia C, Ko, Fred, Resnick, Neil M, McMahon, Siobhan K, Basaria, Shehzad, Wang, Rixin, Lu, Charles, Esserman, Denise, Dziura, James, Miller, Michael E, Travison, Thomas G, Peduzzi, Peter, Bhasin, Shalender, Reuben, David B, and Gill, Thomas M
- Subjects
Health Services and Systems ,Public Health ,Health Sciences ,Clinical Research ,Rehabilitation ,Patient Safety ,Prevention ,Clinical Trials and Supportive Activities ,Aging ,Physical Injury - Accidents and Adverse Effects ,Injuries and accidents ,Good Health and Well Being ,Humans ,Aged ,Quality of Life ,Independent Living ,Fractures ,Bone ,Hospitalization ,care management ,health-related quality of life ,older persons ,pragmatic trials ,falls ,Medical and Health Sciences ,Geriatrics ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
BackgroundFalls are common in older adults and can lead to severe injuries. The Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) trial cluster-randomized 86 primary care practices across 10 health systems to a multifactorial intervention to prevent fall injuries, delivered by registered nurses trained as falls care managers, or enhanced usual care. STRIDE enrolled 5451 community-dwelling older adults age ≥70 at increased fall injury risk.MethodsWe assessed fall-related outcomes via telephone interviews of participants (or proxies) every 4 months. At baseline, 12 and 24 months, we assessed health-related quality of life (HRQOL) using the EQ-5D-5L and EQ-VAS. We used Poisson models to assess intervention effects on falls, fall-related fractures, fall injuries leading to hospital admission, and fall injuries leading to medical attention. We used hierarchical longitudinal linear models to assess HRQOL.ResultsFor recurrent event models, intervention versus control incidence rate ratios were 0.97 (95% confidence interval [CI], 0.93-1.00; p = 0.048) for falls, 0.93 (95% CI, 0.80-1.08; p = 0.337) for self-reported fractures, 0.89 (95% CI, 0.73-1.07; p = 0.205) for adjudicated fractures, 0.91 (95% CI, 0.77-1.07; p = 0.263) for falls leading to hospital admission, and 0.97 (95% CI, 0.89-1.06; p = 0.477) for falls leading to medical attention. Similar effect sizes (non-significant) were obtained for dichotomous outcomes (e.g., participants with ≥1 events). The difference in least square mean change over time in EQ-5D-5L (intervention minus control) was 0.009 (95% CI, -0.002 to 0.019; p = 0.106) at 12 months and 0.005 (95% CI, -0.006 to 0.015; p = 0.384) at 24 months.ConclusionsAcross a standard set of outcomes typically reported in fall prevention studies, we observed modest improvements, one of which was statistically significant. Future work should focus on patient-, practice-, and organization-level operational strategies to increase the real-world effectiveness of interventions, and improving the ability to detect small but potentially meaningful clinical effects.Clinicaltrialsgov identifier: NCT02475850.
- Published
- 2022
7. Engagement of older adults in STRIDE's multifactorial fall injury prevention intervention
- Author
-
McMahon, Siobhan K, Greene, Erich J, Latham, Nancy, Peduzzi, Peter, Gill, Thomas M, Bhasin, Shalender, and Reuben, David B
- Subjects
Health Services and Systems ,Public Health ,Health Sciences ,Clinical Research ,Prevention ,Physical Injury - Accidents and Adverse Effects ,Aging ,Injuries and accidents ,Good Health and Well Being ,Humans ,Aged ,Aged ,80 and over ,Exercise Therapy ,Exercise ,Gait ,Risk Factors ,Fall Prevention ,Older Adults ,Patient Engagement ,Primary Care ,Medical and Health Sciences ,Geriatrics ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
Evidence-based multifactorial fall prevention interventions in clinical practice have been less effective than expected. One plausible reason is that older adults' engagement in fall prevention care is suboptimal. This was a post-hoc analysis of 2403 older adults' engagement in a multifactorial fall prevention intervention in the Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) pragmatic trial. Based on the direct clinical care level of the Patient and Family Continuum of Engagement (CE) framework, three indicators of progressively interactive engagement were assessed: (1) Consultation (receiving information), (2) Involvement (prioritizing risks), and (3) Partnership (identifying prevention actions). Drop off at each step was determined as well as predictors of engagement. The participants' engagement waned with increasingly interactive CE domains. Although all participants received information about their positive fall risk factors (consultation) and most (51%-96%) prioritized them (involvement), fewer participants (33%-55%) identified fall prevention actions (partnership) for most of their risk factors, except for strength gait or balance problems (95%). More participants (70%) identified home exercises than other actions. Finally, fall prevention actions were identified more commonly among participants who received two visits compared to one (OR = 2.33 [95% CI, 2.06-2.64]), were ≥80 years old (OR = 1.83 [95% CI, 1.51-2.23]), and had fewer fall risk factors (OR = 0.90 [95% CI, 0.83-0.99]). The drop-off in participants' engagement based on the level of their interaction with clinicians suggests that future multifactorial fall prevention interventions need to be more focused on interactive patient-clinician partnerships that help older adults increase and maintain fall prevention actions. Our analyses suggest that more frequent contact with clinicians and more monitoring of the implementation and outcomes of Fall Prevention Care Plans could potentially improve engagement and help older adults maintain fall prevention actions.
- Published
- 2022
8. Are serum estrogen concentrations associated with menopausal symptom bother among postmenopausal women? Baseline results from two MsFLASH clinical trials.
- Author
-
Larson, Joseph, Ensrud, Kristine, LaCroix, Andrea, Guthrie, Katherine, Reed, Susan, Bhasin, Shalender, Diem, Susan, and Crandall, Carolyn
- Subjects
Dyspareunia ,Estradiol ,Estrone ,Hot flashes ,Hot flushes ,Joint aches ,Menopause ,Vaginal dryness ,Vasomotor symptoms ,Aged ,Estrogens ,Female ,Hot Flashes ,Humans ,Menopause ,Postmenopause ,Quality of Life ,Sweating - Abstract
OBJECTIVES: To evaluate whether single measurements of serum estradiol (E2), estrone (E1) and sex hormone-binding globulin (SHBG) concentration distinguishes between women with and without menopausal symptom bother. STUDY DESIGN: We analyzed baseline data from two clinical trials conducted in 2012-2017: MsFLASH 03 (178 peri-/post-menopausal women aged 40-62 years with bothersome vasomotor symptoms, mean age 54) and MsFLASH 05 (181 post-menopausal women aged 45-70 years with moderate-to-severe vulvovaginal symptoms, mean age 61). MAIN OUTCOME MEASURES: Symptom bother (hot flushes or flashes, night sweats, sweating, aching in muscles and joints, change in sexual desire, vaginal dryness during intercourse, and avoiding intimacy) in the past month was assessed using the Menopause-Specific Quality of Life questionnaire. Using logistic regression, we calculated the area under the receiver operating characteristic curve (AUC) values for E1, E2, and SHBG concentration in relation to being at least somewhat bothered (symptom bother score ≥3) by each symptom within each trial study population. RESULTS: AUC values (95% confidence interval) ranged between 0.51 (0.41-0.60) and 0.62 (0.53, 0.72) for MsFLASH 03 and between 0.51 (0.42, 0.59) and 0.64 (0.53, 0.75) for MsFLASH 05. There was little evidence of associations between serum hormone levels and bother by a given menopausal symptom. CONCLUSION: These findings do not support the clinical utility of a single measurement of serum of E1, E2, or SHBG concentrations in differentiating between women who are bothered by a given menopausal symptom and those who are not.
- Published
- 2022
9. Maternal Steroid Hormone Levels in Early Pregnancy and Autism in the Offspring: A Population-Based, Nested Case-Control Study
- Author
-
Kosidou, Kyriaki, Karlsson, Håkan, Arver, Stefan, Bhasin, Shalender, Dalman, Christina, and Gardner, Renée M.
- Published
- 2024
- Full Text
- View/download PDF
10. Bone microarchitectural alterations associated with spinal cord injury: Relation to sex hormones, metabolic factors, and loading
- Author
-
Valderrábano, Rodrigo J., Pencina, Karol, Shang, Yili-Valentine, Echevarria, Evelyn, Dixon, Robert, Ghattas, Catherine, Wilson, Lauren, Reid, Kieran F., Storer, Thomas, Garrahan, Margaret, Tedtsen, Trinity, Zafonte, Ross, Bouxsein, Mary, and Bhasin, Shalender
- Published
- 2024
- Full Text
- View/download PDF
11. Costs of fall injuries in the STRIDE study: an economic evaluation of healthcare system heterogeneity and heterogeneity of treatment effect
- Author
-
Ganz, David A., Gill, Thomas M., Reuben, David B., Bhasin, Shalender, Latham, Nancy K., Peduzzi, Peter, and Greene, Erich J.
- Published
- 2023
- Full Text
- View/download PDF
12. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study
- Author
-
Grant, Robert M, Pellegrini, Marion, Defechereux, Patricia A, Anderson, Peter L, Yu, Michelle, Glidden, David V, O’Neal, Joshua, Yager, Jenna, Bhasin, Shalender, Sevelius, Jae, and Deutsch, Madeline B
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Sexual and Gender Minorities (SGM/LGBT*) ,Prevention ,Clinical Research ,Infectious Diseases ,HIV/AIDS ,Adenine ,Anti-HIV Agents ,Emtricitabine ,Estradiol ,Female ,HIV Infections ,Humans ,Male ,Organophosphates ,Pre-Exposure Prophylaxis ,Transgender Persons ,HIV ,preexposure prophylaxis ,transgender ,sex hormones ,pharmacokinetics ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
BackgroundSex hormone and preexposure prophylaxis (PrEP) drug interactions among transgender women (TGW), transgender men (TGM), and cisgender men (CGM) are not fully understood.MethodsTGM and TGW on at least 6 months of stable sex hormone therapy containing testosterone or estradiol (respectively) were enrolled in a 4-week study of directly observed dosing of daily oral coformulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF). TFV-DP in dried blood spots and sex hormones in serum were measured at weekly intervals. TFV-DP was compared with 2- and 4-week samples from Directly Observed Therapy Dried Blood Spots (DOT-DBS) Study (NCT02022657).ResultsFrom May 2017 to June 2018, 24 TGM and 24 TGW were enrolled. Testosterone (total and free) and estradiol concentrations were comparable before and after 4 weeks of PrEP use in TGM and TGW, respectively. Historical controls included 17 cisgender women (CGW) and 15 CGM. TFV-DP concentrations at week 4 were comparable between TGW and TGM (mean difference, -6%; 95% confidence interval [CI], -21% to 12%; P = .47), comparable between TGW and CGM (mean difference, -12%; 95% CI, -27% to 7%; P = .21) and were lower among TGM compared with CGW (mean difference, -23%; 95% CI, -36% to -7%; P = .007). All persons in all groups were projected to reach the TFV-DP threshold that has been associated with high protection from human immunodeficiency virus.ConclusionsCGM, TGM, and TGW had comparable TFV-DP concentrations in dried blood spots after 4 weeks of directly observed daily FTC/TDF PrEP use. Serum hormone concentrations were not affected by FTC/TDF PrEP use.Clinical trials registrationNCT04050371.
- Published
- 2021
13. What Cut-Point in Gait Speed Best Discriminates Community-Dwelling Older Adults With Mobility Complaints From Those Without? A Pooled Analysis From the Sarcopenia Definitions and Outcomes Consortium
- Author
-
Cawthon, Peggy M, Patel, Sheena M, Kritchevsky, Stephen B, Newman, Anne B, Santanasto, Adam, Kiel, Douglas P, Travison, Thomas G, Lane, Nancy, Cummings, Steven R, Orwoll, Eric S, Duchowny, Kate A, Kwok, Timothy, Hirani, Vasant, Schousboe, John, Karlsson, Magnus K, Mellström, Dan, Ohlsson, Claes, Ljunggren, Östen, Xue, Qian-Li, Shardell, Michelle, Jordan, Joanne M, Pencina, Karol M, Fielding, Roger A, Magaziner, Jay, Correa-de-Araujo, Rosaly, Bhasin, Shalender, and Manini, Todd M
- Subjects
Clinical Research ,Aging ,Aged ,Female ,Gait ,Humans ,Independent Living ,Male ,Mobility Limitation ,Sarcopenia ,Walking ,Walking Speed ,Classification and regression trees ,Gait speed ,Mobility limitation ,Clinical Sciences ,Gerontology - Abstract
BackgroundCut-points to define slow walking speed have largely been derived from expert opinion.MethodsStudy participants (13 589 men and 5043 women aged ≥65years) had walking speed (m/s) measured over 4-6 m (mean ± SD: 1.20 ± 0.27 m/s in men and 0.94 ± 0.24 m/s in women.) Mobility limitation was defined as any self-reported difficulty with walking approximately 1/4 mile (prevalence: 12.6% men, 26.4% women). Sex-stratified classification and regression tree (CART) models with 10-fold cross-validation identified walking speed cut-points that optimally discriminated those who reported mobility limitation from those who did not.ResultsAmong 5043 women, CART analysis identified 2 cut-points, classifying 4144 (82.2%) with walking speed ≥0.75 m/s, which we labeled as "fast"; 478 (9.5%) as "intermediate" (walking speed ≥0.62 m/s but
- Published
- 2021
14. Effect of a Multifactorial Fall Injury Prevention Intervention on Patient Well-Being: The STRIDE Study.
- Author
-
Gill, Thomas M, Bhasin, Shalender, Reuben, David B, Latham, Nancy K, Araujo, Katy, Ganz, David A, Boult, Chad, Wu, Albert W, Magaziner, Jay, Alexander, Neil, Wallace, Robert B, Miller, Michael E, Travison, Thomas G, Greenspan, Susan L, Gurwitz, Jerry H, Rich, Jeremy, Volpi, Elena, Waring, Stephen C, Manini, Todd M, Min, Lillian C, Teresi, Jeanne, Dykes, Patricia C, McMahon, Siobhan, McGloin, Joanne M, Skokos, Eleni A, Charpentier, Peter, Basaria, Shehzad, Duncan, Pamela W, Storer, Thomas W, Gazarian, Priscilla, Allore, Heather G, Dziura, James, Esserman, Denise, Carnie, Martha B, Hanson, Catherine, Ko, Fred, Resnick, Neil M, Wiggins, Jocelyn, Lu, Charles, Meng, Can, Goehring, Lori, Fagan, Maureen, Correa-de-Araujo, Rosaly, Casteel, Carri, Peduzzi, Peter, and Greene, Erich J
- Subjects
fall injury prevention ,older persons ,pragmatic trials ,well-being ,Medical and Health Sciences ,Geriatrics - Abstract
Background/objectivesIn the Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) study, a multifactorial intervention was associated with a nonsignificant 8% reduction in time to first serious fall injury but a significant 10% reduction in time to first self-reported fall injury relative to enhanced usual care. The effect of the intervention on other outcomes important to patients has not yet been reported. We aimed to evaluate the effect of the intervention on patient well-being including concern about falling, anxiety, depression, physical function, and disability.DesignPragmatic cluster-randomized trial of 5,451 community-living persons at high risk for serious fall injuries.SettingA total of 86 primary care practices within 10 U.S. healthcare systems.ParticipantsA random subsample of 743 persons aged 75 and older.MeasurementsThe well-being measures, assessed at baseline, 12 months, and 24 months, included a modified version of the Fall Efficacy Scale, Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety and depression scales, and Late-Life Function and Disability Instrument.ResultsParticipants in the intervention (n = 384) and control groups (n = 359) were comparable in age: mean (standard deviation) of 81.9 (4.7) versus 81.8 (5.0) years. Mean scores were similar between groups at 12 and 24 months for concern about falling, physical function, and disability, whereas the intervention group's mean scores on anxiety and depression were .7 points lower (i.e., better) at 12 months and .6 to .8 points lower at 24 months. For each of these outcomes, differences between the groups' adjusted least square mean changes from baseline to 12 and 24 months, respectively, were quantitatively small. The overall difference in means between groups over 2 years was statistically significant only for depression, favoring the intervention: -1.19 (99% confidence interval, -2.36 to -.02), with 3.5 points representing a minimally important difference.ConclusionsSTRIDE's multifactorial intervention to reduce fall injuries was not associated with clinically meaningful improvements in patient well-being.
- Published
- 2021
15. A Multifactorial Trial to Prevent Serious Fall Injuries. Reply.
- Author
-
Bhasin, Shalender, Gill, Thomas M, and Reuben, David B
- Subjects
Biomedical and Clinical Sciences ,Health Sciences ,Accidental Falls ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Published
- 2020
16. Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee
- Author
-
Cawthon, Peggy M., Visser, Marjolein, Arai, Hidenori, Ávila-Funes, José A., Barazzoni, Rocco, Bhasin, Shalender, Binder, Ellen, Bruyère, Olivier, Cederholm, Tommy, Chen, Liang-Kung, Cooper, Cyrus, Duque, Gustavo, Fielding, Roger A., Guralnik, Jack, Kiel, Douglas P., Kirk, Ben, Landi, Francesco, Sayer, Avan A., Von Haehling, Stephan, Woo, Jean, and Cruz-Jentoft, Alfonso J.
- Published
- 2022
- Full Text
- View/download PDF
17. The anabolic applications of androgens in older adults with functional limitations
- Author
-
Gattu, Arijeet K., Goldman, Anna L., Guzelce, Ezgi Caliskan, Galbiati, Francesca, and Bhasin, Shalender
- Published
- 2022
- Full Text
- View/download PDF
18. Prevalence of self-inflicted injuries among transgender and gender diverse adolescents and young adults compared to their peers: an examination of interaction with mental health morbidity
- Author
-
Pampati, Sanjana, Dana Flanders, W., Zhang, Qi, Ahmedani, Brian K., Bhasin, Shalender, Getahun, Darios, Lash, Timothy L., McCracken, Courtney, Sandberg, David E., Silverberg, Michael J., Tangpricha, Vin, Vupputuri, Suma, and Goodman, Michael
- Published
- 2023
- Full Text
- View/download PDF
19. A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries
- Author
-
Bhasin, Shalender, Gill, Thomas M, Reuben, David B, Latham, Nancy K, Ganz, David A, Greene, Erich J, Dziura, James, Basaria, Shehzad, Gurwitz, Jerry H, Dykes, Patricia C, McMahon, Siobhan, Storer, Thomas W, Gazarian, Priscilla, Miller, Michael E, Travison, Thomas G, Esserman, Denise, Carnie, Martha B, Goehring, Lori, Fagan, Maureen, Greenspan, Susan L, Alexander, Neil, Wiggins, Jocelyn, Ko, Fred, Siu, Albert L, Volpi, Elena, Wu, Albert W, Rich, Jeremy, Waring, Stephen C, Wallace, Robert B, Casteel, Carri, Resnick, Neil M, Magaziner, Jay, Charpentier, Peter, Lu, Charles, Araujo, Katy, Rajeevan, Haseena, Meng, Can, Allore, Heather, Brawley, Brooke F, Eder, Rich, McGloin, Joanne M, Skokos, Eleni A, Duncan, Pamela W, Baker, Dorothy, Boult, Chad, Correa-de-Araujo, Rosaly, and Peduzzi, Peter
- Subjects
Health Services ,Aging ,Clinical Trials and Supportive Activities ,Comparative Effectiveness Research ,Physical Injury - Accidents and Adverse Effects ,Patient Safety ,Prevention ,Clinical Research ,Injuries and accidents ,Good Health and Well Being ,Accidental Falls ,Accidental Injuries ,Aged ,Aged ,80 and over ,Female ,Hospitalization ,Humans ,Incidence ,Independent Living ,Male ,Patient Care Management ,Precision Medicine ,Risk Assessment ,Risk Factors ,STRIDE Trial Investigators ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundInjuries from falls are major contributors to complications and death in older adults. Despite evidence from efficacy trials that many falls can be prevented, rates of falls resulting in injury have not declined.MethodsWe conducted a pragmatic, cluster-randomized trial to evaluate the effectiveness of a multifactorial intervention that included risk assessment and individualized plans, administered by specially trained nurses, to prevent fall injuries. A total of 86 primary care practices across 10 health care systems were randomly assigned to the intervention or to enhanced usual care (the control) (43 practices each). The participants were community-dwelling adults, 70 years of age or older, who were at increased risk for fall injuries. The primary outcome, assessed in a time-to-event analysis, was the first serious fall injury, adjudicated with the use of participant report, electronic health records, and claims data. We hypothesized that the event rate would be lower by 20% in the intervention group than in the control group.ResultsThe demographic and baseline characteristics of the participants were similar in the intervention group (2802 participants) and the control group (2649 participants); the mean age was 80 years, and 62.0% of the participants were women. The rate of a first adjudicated serious fall injury did not differ significantly between the groups, as assessed in a time-to-first-event analysis (events per 100 person-years of follow-up, 4.9 in the intervention group and 5.3 in the control group; hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P = 0.25). The rate of a first participant-reported fall injury was 25.6 events per 100 person-years of follow-up in the intervention group and 28.6 events per 100 person-years of follow-up in the control group (hazard ratio, 0.90; 95% CI, 0.83 to 0.99; P = 0.004). The rates of hospitalization or death were similar in the two groups.ConclusionsA multifactorial intervention, administered by nurses, did not result in a significantly lower rate of a first adjudicated serious fall injury than enhanced usual care. (Funded by the Patient-Centered Outcomes Research Institute and others; STRIDE ClinicalTrials.gov number, NCT02475850.).
- Published
- 2020
20. Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone
- Author
-
Shaikh, Kashif, Ellenberg, Susan S, Nakanishi, Rine, Snyder, Peter J, Lee, Juhwan, Wenger, Nanette K, Lewis, Cora E, Swerdloff, Ronald S, Preston, Peter, Hamal, Sajad, Stephens-Sheilds, Alisa, Bhasin, Shalender, Cherukuri, Lavanya, Cauley, Jane A, Crandall, Jill P, Cunningham, Glenn R, Ensrud, Kristine E, Matsumoto, Alvin M, Molich, Mark E, Alla, Venkata M, Birudaraju, Divya, Nezarat, Negin, Rai, Kelash, Almeida, Shone, Roy, Sion K, Sheikh, Mohammad, Trad, George, and Budoff, Mathew J
- Subjects
Heart Disease ,Clinical Research ,Cardiovascular ,Atherosclerosis ,Clinical Trials and Supportive Activities ,Aging ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Aged ,Anthropometry ,Biomarkers ,Coronary Artery Disease ,Disease Progression ,Heart Disease Risk Factors ,Hormone Replacement Therapy ,Humans ,Hypogonadism ,Male ,Plaque ,Atherosclerotic ,Testosterone ,noncalcified coronary artery plaque ,coronary artery disease ,testosterone replacement ,Clinical Sciences ,Paediatrics and Reproductive Medicine ,Endocrinology & Metabolism - Abstract
Recent results from the Cardiovascular Trial of the Testosterone Trials showed that testosterone treatment of older men with low testosterone was associated with greater progression of noncalcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the Testosterone Trial. The Cardiovascular part of the trial included 170 men aged 65 years or older with low testosterone. Participants received testosterone gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of cardiovascular risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. Of 170 enrollees, 138 (73 testosterone, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio (WHR) (P = 0.0014) indicated that this variable impacted the testosterone effect on NCP volume. The statistical model indicated that for every 0.1 change in the WHR, the testosterone-induced 12-month change in NCP volume increased by 26.96 mm3 (95% confidence interval, 7.72-46.20). Among older men with low testosterone treated for 1 year, greater WHR was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.
- Published
- 2020
21. Circulating dihydrotestosterone, testosterone, and free testosterone levels and dihydrotestosterone-to-testosterone ratios in healthy women across the menstrual cycle
- Author
-
Huang, Grace, Bhasin, Shalender, Pencina, Karol, Cheng, Ming, and Jasuja, Ravi
- Published
- 2022
- Full Text
- View/download PDF
22. Benefits and Risks of Testosterone Treatment of Older Men with Hypogonadism
- Author
-
Galbiati, Francesca F., Goldman, Anna L., Gattu, Arijeet, Guzelce, Ezgi Caliskan, and Bhasin, Shalender
- Published
- 2022
- Full Text
- View/download PDF
23. Screening, Recruitment, and Baseline Characteristics for the Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) Study
- Author
-
Gill, Thomas M, McGloin, Joanne M, Latham, Nancy K, Charpentier, Peter A, Araujo, Katy L, Skokos, Eleni A, Lu, Charles, Shelton, Amy, Bhasin, Shalender, Bianco, Luanne M, Carnie, Martha B, Covinsky, Kenneth E, Dykes, Patricia, Esserman, Denise A, Ganz, David A, Gurwitz, Jerry H, Hanson, Catherine, Nyquist, Linda V, Reuben, David B, Wallace, Robert B, and Greene, Erich J
- Subjects
Clinical Research ,Health Services ,Prevention ,Clinical Trials and Supportive Activities ,Good Health and Well Being ,Accidental Falls ,Aged ,80 and over ,Female ,Humans ,Male ,Patient Selection ,Risk Assessment ,Self Concept ,United States ,Recruitment ,Randomized clinical trials ,Serious fall injuries ,Clinical Sciences ,Gerontology - Abstract
BackgroundWe describe the recruitment of participants for Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE), a large pragmatic cluster randomized trial that is testing the effectiveness of a multifactorial intervention to prevent serious fall injuries. Eligible persons were 70 years or older, community-living, and at increased risk for serious fall injuries. The modified goal was to recruit 5,322 participants over 20 months from 86 primary care practices within 10 diverse health care systems across the United States.MethodsThe at-risk population was identified using two distinct but complementary screening strategies that included three questions administered centrally via the mail (nine sites) or in the clinic (one site), while recruitment was completed centrally by staff at Yale.ResultsFor central screening, 226,603 letters mailed to 135,118 patients yielded 28,719 positive screens (12.7% of those mailed and 46.5% of the 61,729 returned). In the clinic, 22,537 screens were completed, leading to 5,732 positive screens (25.4%). Of the 34,451 patients who screened positive for high risk of serious fall injuries, 31,872 were sent a recruitment packet and, of these, 5,451 (17.1%) were enrolled over 20 months (mean age: 80 years; 62% female). The participation rate was 34.0% among eligible patients. The enrollment yields were 3.6% (vs 5% projected) for each patient screened centrally, despite multiple screens, and 10.5% (vs 33.9% projected) for each positive clinic screen.ConclusionsDespite lower-than-expected yields, the STRIDE Study exceeded its modified recruitment goal. If the STRIDE intervention is found to be effective, the two distinct strategies for identifying a high-risk population of older persons could be implemented by most health care systems.
- Published
- 2018
24. Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders
- Author
-
Guzelce, Ezgi Caliskan, Galbiati, Francesca, Goldman, Anna L., Gattu, Arijeet K., Basaria, Shehzad, and Bhasin, Shalender
- Published
- 2022
- Full Text
- View/download PDF
25. Functional replacement of myostatin with GDF-11 in the germline of mice
- Author
-
Lee, Se-Jin, Lehar, Adam, Rydzik, Renata, Youngstrom, Daniel W., Bhasin, Shalender, Liu, Yewei, and Germain-Lee, Emily L.
- Published
- 2022
- Full Text
- View/download PDF
26. Aging researchers in early stages (ARIES): a model for career development collaboration of researchers in aging
- Author
-
Ouchi, Kei, Bhasin, Shalender, and Orkaby, Ariela R.
- Published
- 2021
- Full Text
- View/download PDF
27. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study
- Author
-
Bhasin, Shalender, Lincoff, A. Michael, Basaria, Shehzad, Bauer, Douglas C., Boden, William E., Cunningham, Glenn R., Davey, Deborah, Dubcenco, Elena, Fukumoto, Sandra, Garcia, Michelle, Granger, Christopher B., Kalahasti, Vidyasagar, Khera, Mohit, Miller, Michael G., Mitchell, Lisa M., O'Leary, Michael P., Pencina, Karol M., Snyder, Peter J., Thompson, Ian M., Jr., Travison, Thomas G., Wolski, Kathy, and Nissen, Steven E.
- Published
- 2022
- Full Text
- View/download PDF
28. Transgender Women With Suppressed Testosterone Display Lower Burden of Coronary Disease Than Matched Cisgender Men.
- Author
-
Lake, Jordan E, Feng, Han, Hyatt, Ana N, Miao, Hongyu, Debroy, Paula, Funderburg, Nicholas, Ailstock, Kate, Dobs, Adrian, Haberlen, Sabina, Magnani, Jared W, Margolick, Joseph B, McGowan, Kate, Palella, Frank J, Witt, Mallory D, Bhasin, Shalender, Budoff, Matthew J, Post, Wendy S, and Brown, Todd T
- Subjects
CORONARY artery stenosis ,TRANS women ,CORONARY artery disease ,CORONARY disease ,HORMONE therapy - Abstract
Context Cardiovascular disease (CVD) in transgender women (TW) may be affected by gender-affirming hormone therapy (GAHT) and HIV, but few data compare TW on contemporary GAHT to well-matched controls. Objective We compared CVD burden and biomarker profiles between TW and matched cisgender men (CM). Methods Adult TW on GAHT (n = 29) were recruited for a cross-sectional study (2018-2020). CM (n = 48) from the former Multicenter AIDS Cohort Study were matched 2:1 to TW on HIV serostatus, age ±5 years, race/ethnicity, BMI category and antiretroviral therapy (ART) type. Cardiac parameters were measured by CT and coronary atherosclerosis by coronary CT angiography; sex hormone and biomarker concentrations were measured centrally from stored samples. Results Overall, median age was 53 years and BMI 29 kg/m
2 ; 69% were non-white. All participants with HIV (71%) had viral suppression on ART. Only 31% of TW had testosterone suppression (<50 ng/dL, TW-S). Traditional CVD risk factors were similar between groups, except that TW-S had higher BMI than TW with non-suppressed testosterone (TW-T). TW-S had no evidence of non-calcified coronary plaque or advanced coronary stenosis, whereas TW-T and CM had similar burden. TW had lower prevalence of any coronary plaque, calcified plaque and mixed plaque than CM, regardless of testosterone concentrations and HIV serostatus. Estradiol but not testosterone concentrations moderately and negatively correlated with the presence of coronary plaque and stenosis. Small sample size limited statistical power. Conclusion Older TW with suppressed total testosterone on GAHT had no CT evidence of non-calcified coronary plaque or advanced coronary stenosis. Longitudinal studies to understand relationships between GAHT and CVD risk in TW are needed. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
29. Prostate Risk and Monitoring During Testosterone Replacement Therapy.
- Author
-
Bhasin, Shalender and Thompson, Ian M
- Subjects
PROSTATE ,TESTOSTERONE ,BENIGN prostatic hyperplasia ,PROSTATE cancer patients ,PROSTATE-specific antigen ,OLDER men - Abstract
Abstract Men with hypogonadism have reduced risk of prostate cancer mortality; whether testosterone treatment increases the risk of prostate safety events in men with hypogonadism remains controversial. Several studies including 4 larger randomized trials—the Testosterone Trials, TEstosterone and Atherosclerosis Progression in Aging Men (TEAAM) trial, Testosterone for Diabetes Mellitus trial, and Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) trial—treated men with testosterone or placebo for 1 year or longer and reported prospectively ascertained prostate safety data. The TRAVERSE Trial, because of its large size, longer duration, and adjudication of prostate events, has provided comprehensive data on the risk of adverse prostate events during testosterone replacement therapy (TRT). Among men with hypogonadism, carefully screened to exclude those at high risk of prostate cancer, the incidences of high-grade or any prostate cancer, acute urinary retention, surgical procedure for benign prostatic hyperplasia, prostate biopsy, or new pharmacologic therapy for lower urinary tract symptoms were low and did not differ between the testosterone and placebo groups. Testosterone did not worsen lower urinary tract symptoms. TRT was associated with a greater increase in prostate-specific antigen than placebo in the first year of treatment. Conclusion Testosterone treatment of men with hypogonadism, screened to exclude those at high risk of prostate cancer, is associated with low risk of adverse prostate events. Baseline evaluation of prostate cancer risk and a standardized monitoring plan can minimize the risk of unnecessary prostate biopsy while enabling the detection of high-grade prostate cancers in men receiving TRT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. An executive summary on the Global conceptual definition of Sarcopenia.
- Author
-
Kirk, Ben, Cawthon, Peggy M., Arai, Hidenori, Ávila-Funes, José A., Barazzoni, Rocco, Bhasin, Shalender, Binder, Ellen F., Bruyère, Olivier, Cederholm, Tommy, Chen, Liang-Kung, Cooper, Cyrus, Duque, Gustavo, Fielding, Roger A., Guralnik, Jack, Kiel, Douglas P., Landi, Francesco, Reginster, Jean-Yves, Sayer, Avan A., Visser, Marjolein, and von Haehling, Stephan
- Published
- 2024
- Full Text
- View/download PDF
31. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy.
- Author
-
Bhasin, Shalender, Seidman, Stuart, Travison, Thomas G, Pencina, Karol M, Lincoff, A Michael, Nissen, Steven E, Miller, Michael G, Flevaris, Panagiotis, Li, Xue, Wannemuehler, Kathleen A, and Pope, Harrison G
- Subjects
DEPRESSION in men ,MENTAL depression ,SLEEP quality ,HYPOGONADISM ,MIDDLE-aged men - Abstract
Context The effect of testosterone on depressive symptoms in men with hypogonadism remains incompletely understood. Objective We assessed the effects of testosterone-replacement therapy (TRT) in improving depressive symptoms in hypogonadal men with and without depressive symptoms enrolled in the TRAVERSE cardiovascular safety trial. Methods A randomized, placebo-controlled, double-blind study was conducted at 316 trial sites. Participants included men, aged 45 to 80 years, with 2 fasting testosterone levels less than 300 ng/dL, 1 or more hypogonadal symptoms, cardiovascular disease (CVD), or increased risk of CVD. We evaluated 3 subgroups of participants: (1) men with rigorously defined, late-life-onset, low-grade persistent depressive disorder (LG-PDD, previously "dysthymia"); (2) all men with significant depressive symptoms (Patient Health Questionnaire-9 Score >4); and (3) all randomly assigned men. Intervention included 1.62% transdermal testosterone or placebo gel. Outcome measures included the proportions of participants (1) meeting criteria for LG-PDD or (2) with significant depressive symptoms; and changes in depressive symptoms, energy, sleep quality, and cognition in testosterone-treated vs placebo-treated men in the 3 subgroups. Results Of 5204 randomly assigned participants, 2643 (50.8%) had significant depressive symptoms, but only 49 (1.5%) met rigorous criteria for LG-PDD. Among those with LG-PDD, there was no significant difference in any outcome measure between the TRT and placebo groups, possibly reflecting low statistical power. In men with significant depressive symptoms (n = 2643) and in all randomly assigned participants (n = 5204), TRT was associated with modest but significantly greater improvements in mood and energy but not cognition or sleep quality. Conclusion Depressive symptoms are common in middle-aged and older men with hypogonadism but LG-PDD is uncommon. TRT is associated with small improvements in mood and energy in hypogonadal men with and without significant depressive symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE): A Cluster-Randomized Pragmatic Trial of a Multifactorial Fall Injury Prevention Strategy: Design and Methods
- Author
-
Bhasin, Shalender, Gill, Thomas M, Reuben, David B, Latham, Nancy K, Gurwitz, Jerry H, Dykes, Patricia, McMahon, Siobhan, Storer, Thomas W, Duncan, Pamela W, Ganz, David A, Basaria, Shehzad, Miller, Michael E, Travison, Thomas G, Greene, Erich J, Dziura, James, Esserman, Denise, Allore, Heather, Carnie, Martha B, Fagan, Maureen, Hanson, Catherine, Baker, Dorothy, Greenspan, Susan L, Alexander, Neil, Ko, Fred, Siu, Albert L, Volpi, Elena, Wu, Albert W, Rich, Jeremy, Waring, Stephen C, Wallace, Robert, Casteel, Carri, Magaziner, Jay, Charpentier, Peter, Lu, Charles, Araujo, Katy, Rajeevan, Haseena, Margolis, Scott, Eder, Richard, McGloin, Joanne M, Skokos, Eleni, Wiggins, Jocelyn, Garber, Lawrence, Clauser, Steven B, Correa-De-Araujo, Rosaly, and Peduzzi, Peter
- Subjects
Health Services ,Rehabilitation ,Clinical Research ,Comparative Effectiveness Research ,Patient Safety ,Aging ,Prevention ,Physical Injury - Accidents and Adverse Effects ,Clinical Trials and Supportive Activities ,Prevention of disease and conditions ,and promotion of well-being ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Injuries and accidents ,Good Health and Well Being ,Accidental Falls ,Aged ,Aged ,80 and over ,Female ,Humans ,Male ,Motivational Interviewing ,Risk Assessment ,Wounds and Injuries ,Fall prevention ,Clinical effectiveness ,Patient and stakeholders in fall injury prevention research ,Nurse falls care managers ,Clinical Sciences ,Gerontology - Abstract
BackgroundFall injuries are a major cause of morbidity and mortality among older adults. We describe the design of a pragmatic trial to compare the effectiveness of an evidence-based, patient-centered multifactorial fall injury prevention strategy to an enhanced usual care.MethodsStrategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) is a 40-month cluster-randomized, parallel-group, superiority, pragmatic trial being conducted at 86 primary care practices in 10 health care systems across United States. The 86 practices were randomized to intervention or control group using covariate-based constrained randomization, stratified by health care system. Participants are community-living persons, ≥70 years, at increased risk for serious fall injuries. The intervention is a comanagement model in which a nurse Falls Care Manager performs multifactorial risk assessments, develops individualized care plans, which include surveillance, follow-up evaluation, and intervention strategies. Control group receives enhanced usual care, with clinicians and patients receiving evidence-based information on falls prevention. Primary outcome is serious fall injuries, operationalized as those leading to medical attention (nonvertebral fractures, joint dislocation, head injury, lacerations, and other major sequelae). Secondary outcomes include all fall injuries, all falls, and well-being (concern for falling; anxiety and depressive symptoms; physical function and disability). Target sample size was 5,322 participants to provide 90% power to detect 20% reduction in primary outcome rate relative to control.ResultsTrial enrolled 5,451 subjects in 20 months. Intervention and follow-up are ongoing.ConclusionsThe findings of the STRIDE study will have important clinical and policy implications for the prevention of fall injuries in older adults.
- Published
- 2018
33. Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials
- Author
-
Wang, Christina, Stephens-Shields, Alisa J, DeRogatis, Leonard R, Cunningham, Glenn R, Swerdloff, Ronald S, Preston, Peter, Cella, David, Snyder, Peter J, Gill, Thomas M, Bhasin, Shalender, Matsumoto, Alvin M, and Rosen, Raymond C
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Aging ,Clinical Research ,Clinical Trials and Supportive Activities ,Aged ,Double-Blind Method ,Humans ,Libido ,Male ,Penile Erection ,Reproducibility of Results ,Sexual Behavior ,Sexual Dysfunction ,Physiological ,Surveys and Questionnaires ,Testosterone ,Sexual Desire ,Sexual Activity ,Erectile Function ,Clinically Meaningful Change ,Sexual Function Assessment ,Testosterone Deficiency ,Testosterone Treatment in Older Men ,Testosterone Trials ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Obstetrics & Reproductive Medicine ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
BackgroundLimited information is available on the performance characteristics of 2 questionnaires commonly used in clinical research, the Psychosexual Daily Questionnaire (PDQ) and the Derogatis Interview for Sexual Function (DISF)-II Assessment, especially in older men with low testosterone (T) and impaired sexual function.AimTo determine reliability of PDQ and DISF-II by assessing the correlation within and between domains in the questionnaires and to define clinically meaningful changes in sexual activity (PDQ question 4 [Q4]) and desire (DISF-II sexual desire domain [SDD]) domains.MethodsData from 470 men participating in the T Trials were used to calculate Spearman correlation coefficients of individual items and total score among questionnaires to determine convergent and construct validity. Clinically meaningful changes for sexual desire and activity were determined by randomly dividing the sample into training and validation sets. Anchor- and distribution-based clinically meaningful change criteria were defined in the training set, and selected changes were evaluated in the validation set.OutcomesValidity of the PDQ and DISF-II and clinically meaningful changes in sexual desire and activity were determined in older men in T Trials.ResultsModerate to strong correlations were shown within and between domains from different questionnaires. Using Patient Global Impression of Change as an anchor, clinically meaningful change in PDQ sexual activity was ≥0.6, and in DISF-SDD was ≥5.0. Applying these change cut-points to the validation set, a greater proportion of T-treated men achieved clinically meaningful improvement in their sexual desire and activity compared to placebo-treated men.Clinical implicationsThe PDQ-Q4 and DISF-II-SDD can be used to reliably assess clinically meaningful changes in sexual activity and sexual desire in hypogonadal men treated with T.Strengths & limitationsStrengths of this study include a large sample size, long trial duration, and inclusion of men with low libido and unequivocally low T levels. Limitations include using data from a single study that enrolled only older hypogonadal men, and only 1 anchor for both sexual desire and activity.ConclusionModerate to strong correlations were demonstrated within and between different sexual domains of the PDQ and DISF-II confirming construct and convergent validity. Clinically meaningful improvement in elderly hypogonadal men was change of ≥0.6 score in the PDQ-Q4 and ≥5.0 in the DISF-SDD. Improvements in sexual activity and desire in the T Trials were modest but clinically meaningful. Wang C, Stephens-Shields AJ, DeRogatis LR, et al. Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials. J Sex Med 2018;15:997-1009.
- Published
- 2018
34. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials.
- Author
-
Mohler, Emile R, Ellenberg, Susan S, Lewis, Cora E, Wenger, Nanette K, Budoff, Matthew J, Lewis, Michael R, Barrett-Connor, Elizabeth, Swerdloff, Ronald S, Stephens-Shields, Alisa, Bhasin, Shalender, Cauley, Jane A, Crandall, Jill P, Cunningham, Glenn R, Ensrud, Kristine E, Gill, Thomas M, Matsumoto, Alvin M, Molitch, Mark E, Pahor, Marco, Preston, Peter E, Hou, Xiaoling, Cifelli, Denise, and Snyder, Peter J
- Subjects
Aging ,Cardiovascular ,Prevention ,Clinical Research ,Heart Disease ,Diabetes ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Aged ,Aged ,80 and over ,Biomarkers ,Cardiovascular System ,Double-Blind Method ,Hormone Replacement Therapy ,Humans ,Hypogonadism ,Male ,Testosterone ,United States ,Clinical Sciences ,Paediatrics and Reproductive Medicine ,Endocrinology & Metabolism - Abstract
Context:Studies of the possible cardiovascular risk of testosterone treatment are inconclusive. Objective:To determine the effect of testosterone treatment on cardiovascular biomarkers in older men with low testosterone. Design:Double-blind, placebo-controlled trial. Setting:Twelve academic medical centers in the United States. Participants:In all, 788 men ≥65 years old with an average of two serum testosterone levels
- Published
- 2018
35. Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism
- Author
-
Bhasin, Shalender, primary, Lincoff, A. Michael, additional, Nissen, Steven E., additional, Wannemuehler, Kathleen, additional, McDonnell, Marie E., additional, Peters, Anne L., additional, Khan, Nader, additional, Snabes, Michael C., additional, Li, Xue, additional, Li, Geng, additional, Buhr, Kevin, additional, Pencina, Karol M., additional, and Travison, Thomas G., additional
- Published
- 2024
- Full Text
- View/download PDF
36. Testosterone Treatment and Fractures in Men with Hypogonadism
- Author
-
Snyder, Peter J., primary, Bauer, Douglas C., additional, Ellenberg, Susan S., additional, Cauley, Jane A., additional, Buhr, Kevin A., additional, Bhasin, Shalender, additional, Miller, Michael G., additional, Khan, Nader S., additional, Li, Xue, additional, and Nissen, Steven E., additional
- Published
- 2024
- Full Text
- View/download PDF
37. Estradiol induces allosteric coupling and partitioning of sex-hormone-binding globulin monomers among conformational states
- Author
-
Jasuja, Ravi, Spencer, Daniel, Jayaraj, Abhilash, Peng, Liming, Krishna, Meenakshi, Lawney, Brian, Patel, Priyank, Jayaram, Bhyravabhotla, Thayer, Kelly M., Beveridge, David L., and Bhasin, Shalender
- Published
- 2021
- Full Text
- View/download PDF
38. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial
- Author
-
Snyder, Peter J, Kopperdahl, David L, Stephens-Shields, Alisa J, Ellenberg, Susan S, Cauley, Jane A, Ensrud, Kristine E, Lewis, Cora E, Barrett-Connor, Elizabeth, Schwartz, Ann V, Lee, David C, Bhasin, Shalender, Cunningham, Glenn R, Gill, Thomas M, Matsumoto, Alvin M, Swerdloff, Ronald S, Basaria, Shehzad, Diem, Susan J, Wang, Christina, Hou, Xiaoling, Cifelli, Denise, Dougar, Darlene, Zeldow, Bret, Bauer, Douglas C, and Keaveny, Tony M
- Subjects
Clinical Trials and Supportive Activities ,Clinical Research ,Prevention ,Osteoporosis ,Aging ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Musculoskeletal ,Absorptiometry ,Photon ,Aged ,Androgens ,Bone Density ,Double-Blind Method ,Drug Administration Routes ,Drug Monitoring ,Hip Fractures ,Humans ,Lumbar Vertebrae ,Male ,Spinal Fractures ,Testosterone ,Tomography ,X-Ray Computed ,Treatment Outcome ,Clinical Sciences ,Opthalmology and Optometry ,Public Health and Health Services - Abstract
ImportanceAs men age, they experience decreased serum testosterone concentrations, decreased bone mineral density (BMD), and increased risk of fracture.ObjectiveTo determine whether testosterone treatment of older men with low testosterone increases volumetric BMD (vBMD) and estimated bone strength.Design, setting, and participantsPlacebo-controlled, double-blind trial with treatment allocation by minimization at 9 US academic medical centers of men 65 years or older with 2 testosterone concentrations averaging less than 275 ng/L participating in the Testosterone Trials from December 2011 to June 2014. The analysis was a modified intent-to-treat comparison of treatment groups by multivariable linear regression adjusted for balancing factors as required by minimization.InterventionsTestosterone gel, adjusted to maintain the testosterone level within the normal range for young men, or placebo gel for 1 year.Main outcomes and measuresSpine and hip vBMD was determined by quantitative computed tomography at baseline and 12 months. Bone strength was estimated by finite element analysis of quantitative computed tomography data. Areal BMD was assessed by dual energy x-ray absorptiometry at baseline and 12 months.ResultsThere were 211 participants (mean [SD] age, 72.3 [5.9] years; 86% white; mean [SD] body mass index, 31.2 [3.4]). Testosterone treatment was associated with significantly greater increases than placebo in mean spine trabecular vBMD (7.5%; 95% CI, 4.8% to 10.3% vs 0.8%; 95% CI, -1.9% to 3.4%; treatment effect, 6.8%; 95% CI, 4.8%-8.7%; P
- Published
- 2017
39. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone
- Author
-
Budoff, Matthew J, Ellenberg, Susan S, Lewis, Cora E, Mohler, Emile R, Wenger, Nanette K, Bhasin, Shalender, Barrett-Connor, Elizabeth, Swerdloff, Ronald S, Stephens-Shields, Alisa, Cauley, Jane A, Crandall, Jill P, Cunningham, Glenn R, Ensrud, Kristine E, Gill, Thomas M, Matsumoto, Alvin M, Molitch, Mark E, Nakanishi, Rine, Nezarat, Negin, Matsumoto, Suguru, Hou, Xiaoling, Basaria, Shehzad, Diem, Susan J, Wang, Christina, Cifelli, Denise, and Snyder, Peter J
- Subjects
Aging ,Clinical Trials and Supportive Activities ,Cardiovascular ,Heart Disease ,Atherosclerosis ,Heart Disease - Coronary Heart Disease ,Prevention ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Aged ,Androgens ,Coronary Angiography ,Coronary Artery Disease ,Disease Progression ,Double-Blind Method ,Gels ,Hormone Replacement Therapy ,Humans ,Hypogonadism ,Male ,Observer Variation ,Sample Size ,Testosterone ,United States ,Vascular Calcification ,Medical and Health Sciences ,General & Internal Medicine - Abstract
ImportanceRecent studies have yielded conflicting results as to whether testosterone treatment increases cardiovascular risk.ObjectiveTo test the hypothesis that testosterone treatment of older men with low testosterone slows progression of noncalcified coronary artery plaque volume.Design, setting, and participantsDouble-blinded, placebo-controlled trial at 9 academic medical centers in the United States. The participants were 170 of 788 men aged 65 years or older with an average of 2 serum testosterone levels lower than 275 ng/dL (82 men assigned to placebo, 88 to testosterone) and symptoms suggestive of hypogonadism who were enrolled in the Testosterone Trials between June 24, 2010, and June 9, 2014.InterventionTestosterone gel, with the dose adjusted to maintain the testosterone level in the normal range for young men, or placebo gel for 12 months.Main outcomes and measuresThe primary outcome was noncalcified coronary artery plaque volume, as determined by coronary computed tomographic angiography. Secondary outcomes included total coronary artery plaque volume and coronary artery calcium score (range of 0 to >400 Agatston units, with higher values indicating more severe atherosclerosis).ResultsOf 170 men who were enrolled, 138 (73 receiving testosterone treatment and 65 receiving placebo) completed the study and were available for the primary analysis. Among the 138 men, the mean (SD) age was 71.2 (5.7) years, and 81% were white. At baseline, 70 men (50.7%) had a coronary artery calcification score higher than 300 Agatston units, reflecting severe atherosclerosis. For the primary outcome, testosterone treatment compared with placebo was associated with a significantly greater increase in noncalcified plaque volume from baseline to 12 months (from median values of 204 mm3 to 232 mm3 vs 317 mm3 to 325 mm3, respectively; estimated difference, 41 mm3; 95% CI, 14 to 67 mm3; P = .003). For the secondary outcomes, the median total plaque volume increased from baseline to 12 months from 272 mm3 to 318 mm3 in the testosterone group vs from 499 mm3 to 541 mm3 in the placebo group (estimated difference, 47 mm3; 95% CI, 13 to 80 mm3; P = .006), and the median coronary artery calcification score changed from 255 to 244 Agatston units in the testosterone group vs 494 to 503 Agatston units in the placebo group (estimated difference, -27 Agatston units; 95% CI, -80 to 26 Agatston units). No major adverse cardiovascular events occurred in either group.Conclusions and relevanceAmong older men with symptomatic hypogonadism, treatment with testosterone gel for 1 year compared with placebo was associated with a significantly greater increase in coronary artery noncalcified plaque volume, as measured by coronary computed tomographic angiography. Larger studies are needed to understand the clinical implications of this finding.Trial registrationclinicaltrials.gov Identifier: NCT00799617.
- Published
- 2017
40. Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men: Individual Participant Data Meta-analyses.
- Author
-
Yeap, Bu B., Marriott, Ross J., Dwivedi, Girish, Adams, Robert J., Antonio, Leen, Ballantyne, Christie M., Bauer, Douglas C., Bhasin, Shalender, Biggs, Mary L., Cawthon, Peggy M., Couper, David J., Dobs, Adrian S., Flicker, Leon, Handelsman, David J., Hankey, Graeme J., Hannemann, Anke, Haring, Robin, Hsu, Benjumin, Martin, Sean A., and Matsumoto, Alvin M.
- Subjects
CARDIOVASCULAR disease related mortality ,MORTALITY ,CARDIOVASCULAR diseases ,HDL cholesterol ,SEX hormones ,OLDER men - Abstract
The relationship between testosterone and related hormones and cardiovascular and mortality outcomes is debated. The authors of this study obtained individual patient–level data from 9 cohort studies and aggregate data from 11 studies in total. These data enabled them to describe the associations of testosterone, sex hormone–binding globulin (SHBG), luteinizing hormone (LH), dihydrotestosterone (DHT), and estradiol with all-cause mortality, cardiovascular death, and incident cardiovascular events while accounting for other cardiac risk factors. Background: Whether circulating sex hormones modulate mortality and cardiovascular disease (CVD) risk in aging men is controversial. Purpose: To clarify associations of sex hormones with these outcomes. Data Sources: Systematic literature review to July 2019, with bridge searches to March 2024. Study Selection: Prospective cohort studies of community-dwelling men with sex steroids measured using mass spectrometry and at least 5 years of follow-up. Data Extraction: Independent variables were testosterone, sex hormone–binding globulin (SHBG), luteinizing hormone (LH), dihydrotestosterone (DHT), and estradiol concentrations. Primary outcomes were all-cause mortality, CVD death, and incident CVD events. Covariates included age, body mass index, marital status, alcohol consumption, smoking, physical activity, hypertension, diabetes, creatinine concentration, ratio of total to high-density lipoprotein cholesterol, and lipid medication use. Data Synthesis: Nine studies provided individual participant data (IPD) (255 830 participant-years). Eleven studies provided summary estimates (n = 24 109). Two-stage random-effects IPD meta-analyses found that men with baseline testosterone concentrations below 7.4 nmol/L (<213 ng/dL), LH concentrations above 10 IU/L, or estradiol concentrations below 5.1 pmol/L had higher all-cause mortality, and those with testosterone concentrations below 5.3 nmol/L (<153 ng/dL) had higher CVD mortality risk. Lower SHBG concentration was associated with lower all-cause mortality (median for quintile 1 [Q1] vs. Q5, 20.6 vs. 68.3 nmol/L; adjusted hazard ratio [HR], 0.85 [95% CI, 0.77 to 0.95]) and lower CVD mortality (adjusted HR, 0.81 [CI, 0.65 to 1.00]). Men with lower baseline DHT concentrations had higher risk for all-cause mortality (median for Q1 vs. Q5, 0.69 vs. 2.45 nmol/L; adjusted HR, 1.19 [CI, 1.08 to 1.30]) and CVD mortality (adjusted HR, 1.29 [CI, 1.03 to 1.61]), and risk also increased with DHT concentrations above 2.45 nmol/L. Men with DHT concentrations below 0.59 nmol/L had increased risk for incident CVD events. Limitations: Observational study design, heterogeneity among studies, and imputation of missing data. Conclusion: Men with low testosterone, high LH, or very low estradiol concentrations had increased all-cause mortality. SHBG concentration was positively associated and DHT concentration was nonlinearly associated with all-cause and CVD mortality. Primary Funding Source: Medical Research Future Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: CRD42019139668) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Transgender Patients Report Lower Satisfaction with Care Received than Cisgender Patients Receiving Care in an Academic Medical Care System.
- Author
-
Mai-Han Trinh, Quint, Meg, Coon, Devin, Bhasin, Shalender, Tocci, Benjamin, and Reisner, Sari L.
- Published
- 2024
- Full Text
- View/download PDF
42. Testosterone Deficiency and Other Testicular Disorders in Kidney Disease
- Author
-
Goldman, Anna L., Bhasin, Shalender, Rhee, Connie M., editor, Kalantar-Zadeh, Kamyar, editor, and Brent, Gregory A., editor
- Published
- 2019
- Full Text
- View/download PDF
43. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism
- Author
-
Bhasin, Shalender, primary, Travison, Thomas G., additional, Pencina, Karol M., additional, O’Leary, Michael, additional, Cunningham, Glenn R., additional, Lincoff, A. Michael, additional, Nissen, Steven E., additional, Lucia, M. Scott, additional, Preston, Mark A., additional, Khera, Mohit, additional, Khan, Nader, additional, Snabes, Michael C., additional, Li, Xue, additional, Tangen, Catherine M., additional, Buhr, Kevin A., additional, and Thompson, Ian M., additional
- Published
- 2023
- Full Text
- View/download PDF
44. Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study
- Author
-
Grant, Bonnie, primary, Campbell, John, additional, Pradeep, Anjali, additional, Burns, Angela D, additional, Bassett, Paul, additional, Abbara, Ali, additional, Saket, Priyadarshi, additional, Minhas, Sukhbinder, additional, Dhillo, Waljit S, additional, McVeigh, James, additional, Bhasin, Shalender, additional, and Jayasena, Channa N, additional
- Published
- 2023
- Full Text
- View/download PDF
45. Sex hormone binding globulin and total testosterone levels are associated with in vivo tau burden differentially between the sexes: findings from the Framingham Study
- Author
-
Buckley, Rachel F., primary, McGrath, Emer R, additional, Scott, Matthew R, additional, Coughlan, Gillian T, additional, Boyle, Rory, additional, Seto, Mabel, additional, Ghosh, Saptaparni, additional, Jacobs, Heidi I.L., additional, Satizabal, Claudia L., additional, Thibault, Emma G., additional, Vasan, Ramachandran S, additional, Murabito, Joanne M, additional, Sperling, Reisa A., additional, Johnson, Keith A., additional, Seshadri, Sudha, additional, Jasuja, Ravi, additional, Bhasin, Shalender, additional, and Beiser, Alexa S., additional
- Published
- 2023
- Full Text
- View/download PDF
46. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
- Author
-
Hudson, Jemma, primary, Cruickshank, Moira, additional, Quinton, Richard, additional, Aucott, Lorna, additional, Wu, Frederick, additional, Grossmann, Mathis, additional, Bhasin, Shalender, additional, Snyder, Peter J, additional, Ellenberg, Susan S, additional, Travison, Thomas G, additional, Brock, Gerald B, additional, Gianatti, Emily J, additional, van der Schouw, Yvonne T, additional, Emmelot-Vonk, Marielle H, additional, Giltay, Erik J, additional, Hackett, Geoff, additional, Ramachandran, Sudarshan, additional, Svartberg, Johan, additional, Hildreth, Kerry L, additional, Antonic, Kristina Groti, additional, Tenover, Joyce Lisa, additional, Tan, Hui Meng, additional, Ho Chee Kong, Christopher, additional, Tan, Wei Shen, additional, Marks, Leonard S, additional, Ross, Richard J, additional, Schwartz, Robert S, additional, Manson, Paul, additional, Roberts, Stephen A, additional, Skovsager Andersen, Marianne, additional, Velling Magnussen, Line, additional, Aceves-Martins, Magaly, additional, Gillies, Katie, additional, Hernández, Rodolfo, additional, Oliver, Nick, additional, Dhillo, Waljit S, additional, Bhattacharya, Siladitya, additional, Brazzelli, Miriam, additional, and Jayasena, Channa N, additional
- Published
- 2023
- Full Text
- View/download PDF
47. OR25-05 Clinical Predictors Of Symptomatic Benefit In Men With Low Testosterone During Testosterone Treatment Compared With Placebo: Results Of Individual Patient And Aggregate Data Meta-analyses
- Author
-
Hudson, Jemma, primary, Cruickshank, Moira, additional, Quinton, Richard, additional, Aucott, Lorna, additional, Wu, Frederick C, additional, Grossmann, Mathis, additional, Bhasin, Shalender, additional, Snyder, Peter J, additional, Ellenberg, Susan, additional, Travison, Thomas G, additional, Brock, Gerald B, additional, Jaye Gianatti, Emily, additional, van der Schouw, Yvonne T, additional, Emmelot-Vonk, Marielle H, additional, Giltay, Erik J, additional, Geoff, Hackett, additional, Ramachandran, Sudarshan, additional, Bernhard Svartberg, Johan, additional, Hildreth, Kerry L, additional, Groti Antonic, Kristina, additional, Tenover, Joyce S, additional, Meng Tan, Hui, additional, Chee Kong, Christopher Ho, additional, Wei Shen, Tan, additional, Marks, Leonard S, additional, Ross, Richard John M, additional, Schwartz, Robert S, additional, Roberts, Stephen, additional, Andersen, Marianne, additional, Magnussen, Line, additional, Aceves-Martins, Magaly, additional, Bhattacharya, Siladitya, additional, Singh Dhillo, Waljit, additional, Brazzelli, Miriam, additional, and Nalin Jayasena, Channa, additional
- Published
- 2023
- Full Text
- View/download PDF
48. THU652 Associations Of Testosterone, Dihydrotestosterone, Estradiol And Sex Hormone-binding Globulin With All-cause And Cardiovascular Mortality, And Incident Cardiovascular Events In Men: Individual Participant Data Meta-analyses
- Author
-
Yeap, Bu Beng, primary, Marriott, Ross J, additional, Antonio, Leen, additional, Bhasin, Shalender, additional, Dobs, Adrian S, additional, Handelsman, David J, additional, Hankey, Graeme J, additional, Haring, Robin, additional, Matsumoto, Alvin M, additional, Ohlsson, Claes, additional, Orwoll, Eric S, additional, Vanderschueren, Dirk M, additional, Wittert, Gary Allen, additional, Wu, Frederick C, additional, and Murray, Kevin, additional
- Published
- 2023
- Full Text
- View/download PDF
49. OR25-03 Self-administration Of Post-cycle Therapy Is Associated With Increased Probability Of Subsequent Normalisation Of Reproductive Hormones Following Anabolic-androgenic Steroid Cessation In Men
- Author
-
Grant, Bonnie, primary, Campbell, John, additional, Pradeep, Anjali, additional, Dawn Burns, Angela, additional, Bassett, Paul, additional, Saket, Priyadarshi, additional, Minhas, Sukhbinder, additional, Singh Dhillo, Waljit, additional, McVeigh, James, additional, Bhasin, Shalender, additional, and Nalin Jayasena, Channa, additional
- Published
- 2023
- Full Text
- View/download PDF
50. OR25-04 Factors Affecting Testosterone Concentrations In Men: Individual Participant Data Meta-analyses From The Androgens In Men Study
- Author
-
Marriott, Ross J, primary, Murray, Kevin, additional, Antonio, Leen, additional, Bhasin, Shalender, additional, Sandra Dobs, Adrian, additional, Handelsman, David J, additional, Hankey, Graeme J, additional, Haring, Robin, additional, Matsumoto, Alvin M, additional, Ohlsson, Claes, additional, Orwoll, Eric S, additional, Vanderschueren, Dirk M, additional, Allen Wittert, Gary, additional, Wu, Frederick C, additional, and Beng Yeap, Bu, additional
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.